- Residency - UT Southwestern Medical Center (2013-2016), Dermatology
- Internship - Texas Health Presbyterian Hospital Dallas (2012-2013), Internal Medicine
- Medical School - Washington University School of Medicine (2003-2012)
- Graduate School - Washing University School of Medicine in St. Louis (2003-2012)
Jennifer Gill, M.D., Ph.D.
- Dermatology - General
Jennifer G. Gill, M.D., Ph.D., is an Instructor in the Department of Dermatology at UT Southwestern Medical Center. Her clinical specialties include treating melanoma and dermatologic complications of cancer, such as cutaneous metastases and chemotherapy-related rashes.
Dr. Gill earned her medical and doctoral degrees in immunology through the Medical Scientist Training Program at Washington University School of Medicine in St. Louis. She completed a dermatology residency – including both clinical and research experience – at UT Southwestern and an internal medicine internship at Texas Health Presbyterian Hospital Dallas.
She currently performs research at Children’s Medical Center Research Institute at UT Southwestern, where she is working to identify the molecular mechanisms behind melanoma metastasis and distant organ tropism. She also holds a Bachelor of Science degree in cellular biology from the University of Georgia.
Dr. Gill’s research interests include targeted cancer therapies and metastasis of melanoma and other cancers. She has published a number of journal articles and contributed to the third edition of Comprehensive Dermatologic Drug Therapy.
Her professional activities also include serving as a peer reviewer for the American Academy of Dermatology and as the Basic Science editor for the Academy’s Board Preparation Question Bank.
Among her many honors, Dr. Gill received the American Academy of Dermatology’s 2018 Presidential Citation Award and the Dermatology Foundation’s 2017 Career Development Award. She is also a prior recipient of the prestigious Barry M. Goldwater Scholarship, an award created by the U.S. Congress for young scientists with exceptional potential.
Certified by the American Board of Dermatology, Dr. Gill is a member of professional organizations that include the American Academy of Dermatology and the Society for Investigative Dermatology, on whose board of directors she also serves.
She joined the UT Southwestern faculty in 2016.
- Society for Investigative Dermatology (2013)
- American Academy of Dermatology (2013)
- University of Georgia Foundation Fellowship Scholarship 1999-2003
- Barry M. Goldwater National Scholarship 2002
- American Physician Scientist Association Travel Award Recipient 2009
- Texas Health Presbyterian Hospital Intern of the Year Award 2013
- Physician Scientist Training Program Grant Recipient 2015
- Dermatology Resident Award for Humanism and Professionalism 2015
- UTSW Dermatology Resident Award for Leadership 2016
- Dermatologist Investigator Research Fellowship 2016
- Dermatology Foundation Physician-Scientist Career Development Award 2017
Rituximab and Future Biologic Therapies in Comprehensive Dermatologic Drug Therapy, 3rd Edition
Leonardi, CL, Heffernan, MP, and Gill, JG (2012), Saunders Publishing Company
- Rituximab and Future Biologic Therapies in Comprehensive Dermatologic Drug Therapy, 3rd Edition
Cancer, Oxidative Stress, and Metastasis.
Gill JG, Piskounova E, Morrison SJ Cold Spring Harbor symposia on quantitative biology 2017 Jan
Snail promotes the cell-autonomous generation of Flk1(+) endothelial cells through the repression of the microRNA-200 family.
Gill JG, Langer EM, Lindsley RC, Cai M, Murphy TL, Murphy KM Stem cells and development 2012 Jan 21 2 167-76
Dual actions of Meis1 inhibit erythroid progenitor development and sustain general hematopoietic cell proliferation.
Cai M, Langer EM, Gill JG, Satpathy AT, Albring JC, KC W, Murphy TL, Murphy KM Blood 2012 Jul 120 2 335-46
Snail and the microRNA-200 family act in opposition to regulate epithelial-to-mesenchymal transition and germ layer fate restriction in differentiating ESCs.
Gill JG, Langer EM, Lindsley RC, Cai M, Murphy TL, Kyba M, Murphy KM Stem cells (Dayton, Ohio) 2011 May 29 5 764-76
Cutaneous manifestations of chemotherapeutic drugs
Gill JG and Dominguez A Current Dermatology Reports 2016 5 1
Canonical Wnt signaling is required for development of embryonic stem cell-derived mesoderm.
Lindsley RC, Gill JG, Kyba M, Murphy TL, Murphy KM Development (Cambridge, England) 2006 Oct 133 19 3787-96
Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.
Frankel AE, Eskiocak U, Gill JG, Yuan S, Ramesh V, Froehlich TW, Ahn C, Morrison SJ Neoplasia (New York, N.Y.) 2017 Mar 19 4 255-260
Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma.
Eskiocak U, Ramesh V, Gill JG, Zhao Z, Yuan SW, Wang M, Vandergriff T, Shackleton M, Quintana E, Johnson TM, DeBerardinis RJ, Morrison SJ Nature communications 2016 7 12336
Mesp1 coordinately regulates cardiovascular fate restriction and epithelial-mesenchymal transition in differentiating ESCs.
Lindsley RC, Gill JG, Murphy TL, Langer EM, Cai M, Mashayekhi M, Wang W, Niwa N, Nerbonne JM, Kyba M, Murphy KM Cell stem cell 2008 Jul 3 1 55-68
- Cancer, Oxidative Stress, and Metastasis.
- Targeted therapies for treatment of cancer
- Melanoma metastasis
- Cancer metastasis